Italian observational study on T-DM1 in HER2 positive advanced breast cancer patients: real world effectiveness and safety

被引：0
|
作者：
Fabi, A. [1 ]
Alesini, D. [1 ]
De laurentiis, M. [2 ]
Valle, E. [3 ]
Santini, D. [4 ]
Cannita, K. [5 ]
Carbognin, L. [6 ]
Ciccarese, M. [7 ]
Arpino, G. [8 ]
Leonardi, V. [9 ]
Montemurro, F. [10 ]
La Verde, N. [11 ]
Generali, D. G. [12 ]
Scandurra, G. [13 ]
Russillo, M. [14 ]
Paris, I. [15 ]
D'Ottavio, A. M. [16 ]
Filippelli, G. [17 ]
Stani, S. [18 ]
Giannarelli, D. [1 ]
Cognetti, F. [1 ]
机构：
[1] Ist Nazl Tumori Regina Elena, Rome, Italy
[2] Fdn Pascale, Ist Nazl Tumori, Naples, Italy
[3] Osped A Businco, Cagliari, Italy
[4] Campus Bio Med, Rome, Italy
[5] Presidio Osped S Salvatore, Laquila, Italy
[6] Azienda Univ Integrata Verona, Verona, Italy
[7] Osped Vito Fazzi, Lecce, Italy
[8] Univ Federico II, Naples, Italy
[9] ARNAS Civ, Palermo, Italy
[10] Fdn Piemonte Oncol, Candiolo, Italy
[11] Osped San Raffaele, Milan, Italy
[12] Ist Osped, Cremona, Italy
[13] Osped Oncol, Catania, Italy
[14] Osped Oncol, Lucca, Italy
[15] Univ Cattolica Sacro Cuore A Gemelli, Rome, Italy
[16] Osped S Giovanni Addolorata, Rome, Italy
[17] Osped S Francesco Paola, Paola, Italy
[18] Osped Santo Spirito, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw337.7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
F07
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Activity of T-DM1 in Her2-positive breast cancer brain metastases
    Rupert Bartsch
    Anna S. Berghoff
    Ursula Vogl
    Margaretha Rudas
    Elisabeth Bergen
    Peter Dubsky
    Karin Dieckmann
    Katja Pinker
    Zsuzsanna Bago-Horvath
    Arik Galid
    Leopold Oehler
    Christoph C. Zielinski
    Michael Gnant
    Guenther G. Steger
    Matthias Preusser
    Clinical & Experimental Metastasis, 2015, 32 : 729 - 737
  • [42] T-DM1 in HER2-positive breast cancer brain metastases (BM).
    Bartsch, Rupert
    Berghoff, Anna Sophie
    Rudas, Margareta
    Bergen, Elisabeth
    Gnant, Michael
    Dieckmann, Karin
    Pinker, Katja
    Zielinski, Christoph
    Steger, Guenther G.
    Preusser, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Activity of T-DM1 in Her2-positive breast cancer brain metastases
    Bartsch, Rupert
    Berghoff, Anna S.
    Vogl, Ursula
    Rudas, Margaretha
    Bergen, Elisabeth
    Dubsky, Peter
    Dieckmann, Karin
    Pinker, Katja
    Bago-Horvath, Zsuzsanna
    Galid, Arik
    Oehler, Leopold
    Zielinski, Christoph C.
    Gnant, Michael
    Steger, Guenther G.
    Preusser, Matthias
    CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (07) : 729 - 737
  • [44] T-DM1 is active in Her2-positive breast cancer brain metastases
    Bartsch, R.
    Berghoff, A.
    Rudas, M.
    Bergen, E.
    Gnant, M.
    Dieckmann, K.
    Pinker, K.
    Zielinski, C. C.
    Steger, G. G.
    Preusser, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 195 - 195
  • [45] A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+breast cancer
    Krop, I. E.
    Mita, M.
    Burris, H. A.
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Modi, S.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [46] Efficacy and safety of T-DM1 in the 'common-practice' of HER2+advanced breast cancer setting: a multicenter study
    Fabi, Alessandra
    De laurentiis, Michelino
    Caruso, Michele
    Valle, Enrichetta
    Moscetti, Luca
    Santini, Daniele
    Cannita, Katia
    Carbognin, Luisa
    Ciccarese, Mariangela
    Rossello, Rosalba
    Arpino, Grazia
    Leonardi, Vita
    Montemurro, Filippo
    La Verde, Nicla
    Generali, Daniele
    Zambelli, Alberto
    Scandurra, Giuseppa
    Russillo, Michelangelo
    Paris, Ida
    D'Ottavio, Anna Maria
    Filippelli, Gianfranco
    Giampaglia, Marianna
    Stani, Simonetta
    Fabbri, Agnese
    Alesini, Daniele
    Cianniello, Daniela
    Giannarelli, Diana
    Cognetti, Francesco
    ONCOTARGET, 2017, 8 (38) : 64481 - 64489
  • [47] HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1
    Braso-Maristany, F.
    Griguolo, G.
    Chic, N.
    Pare Brunet, L.
    Galvan, P.
    Dieci, M. V.
    Miglietta, F.
    Giarratano, T.
    Martinez-Saez, O.
    Marin, M.
    Vidal Losada, M. J.
    Adamo, B.
    Munoz, M.
    Vivancos, A.
    Villagrasa Gonzalez, P.
    Parker, J.
    Perou, C. M.
    Conte, P. F.
    Prat, A.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S646 - S646
  • [48] Real world outcomes in elderly women with HER2 positive advanced breast cancer
    Evans, Nicole
    Anton, Angelyn
    Wong, Rachel
    Lok, Sheau Wen
    De Boer, Richard
    Malik, Laeeq
    Greenberg, Sally
    Yeo, Belinda
    Nott, Louise
    Richardson, Gary
    Collins, Ian M.
    Torres, Javier
    Barnett, Frances
    Gibbs, Peter
    Devitt, Bianca
    CANCER RESEARCH, 2021, 81 (04)
  • [49] A retrospective population-based observational study in metastatic HER2-positive breast cancer patients in Denmark previously treated with T-DM1
    Due, A.
    Berg, T.
    Jensen, M-B.
    Knoop, A.
    Kumler, I.
    Andersen, K. K.
    Rana, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S490 - S490
  • [50] HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
    Rinnerthaler, Gabriel
    Gampenrieder, Simon Peter
    Greil, Richard
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (05)
12345